Evicenter
MarkdownMedical informationP&T meetings
Vonaprument (ANX007)

Geographic atrophy secondary to age-related macular degeneration

Launch
Not announced
Last updated
167 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Antioxidant vitamin and mineral supplementation

4 evidence topics · 5 sources

AREDS formulation and progression to advanced AMD

“Participants were randomly assigned to receive daily oral tablets containing: (1) antioxidants (vitamin C, 500 mg; vitamin E, 400 IU; and beta carotene, 15 mg); (2) zinc, 80 mg, as zinc oxide and copper, 2 mg, as cupric oxide; (3) antioxidants plus zinc; or (4) placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Average follow-up of the 3640 enrolled study participants, aged 55–80 years, was 6.3 years, with 2.4% lost to follow-up. Comparison with placebo demonstrated a statistically significant odds reduction for the development of advanced AMD with antioxidants plus zinc (odds ratio [OR], 0.72; 99% confidence interval [CI], 0.52–0.98).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The only statistically significant reduction in rates of at least moderate visual acuity loss occurred in persons assigned to receive antioxidants plus zinc (OR, 0.73; 99% CI, 0.54–0.99).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Those with extensive intermediate size drusen, at least 1 large druse, noncentral geographic atrophy in 1 or both eyes, or advanced AMD or vision loss due to AMD in 1 eye, and without contraindications such as smoking, should consider taking a supplement of antioxidants plus zinc such as that used in this study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Supplementation and geographic atrophy progression toward the fovea: post hoc analysis of AREDS and AREDS2

“Post hoc analysis of the Age-Related Eye Diseases Study (AREDS) and AREDS2, multi-center randomized placebo-controlled trials of oral micronutrient supplementation, each with 2×2 factorial design.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“392 eyes (318 participants) with GA in AREDS; 1210 eyes (891 participants) with GA in AREDS2.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In AREDS eyes with non-central GA (n=208), proximity-based progression towards the central macula was significantly slower with randomization to antioxidants versus none, at 50.7 μm/year (95% CI 38.0–63.4 μm/year) versus 72.9 μm/year (95% CI 61.3–84.5 μm/year; p=0.012), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In AREDS2 eyes with non-central GA, in participants assigned to AREDS antioxidants without β-carotene (n=325 eyes), proximity-based progression was significantly slower with randomization to lutein/zeaxanthin versus none, at 80.1 μm/year (95% CI 60.9–99.3 μm/year) versus 114.4 μm/year (95% CI 96.2–132.7 μm/year; p=0.011), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In AREDS eyes with any GA (n=392), area-based progression was not significantly different with randomization to antioxidants versus none (p=0.63).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Oral micronutrient supplementation slowed GA progression towards the central macula, likely by augmenting the natural phenomenon of foveal sparing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote